A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Solid Tumor
Interventions: DRUG: Farletuzumab ecteribulin|DRUG: Prednisone|DRUG: Prednisolone|DRUG: Dexamethasone
Sponsor: Eisai Inc.
Collaborators: Bristol-Myers Squibb